BioCentury
ARTICLE | Company News

Intrexon deal

April 11, 2016 7:00 AM UTC

Intrexon and a group of investors led by White Rock Capital Partners formed JV T1D Partners LLC to use the biotech’s ActoBiotics drug delivery technology to develop an antigen-specific immunotherapy t...